Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer

Park, Yong Hyun; Hwang, In Sik; Jeong, Chang Wook; Kim, Hyeon Hoe; Lee, Sang Eun; Kwak, Cheol

doi:10.1016/j.juro.2009.01.104

Cited by 38 publications

(43 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study demonstrated that ADT patient is more likely to retain HSPC if, after PSA values reach nadir, PSA level decreases more than 0.048 ng/ml during a month, then the decrease occurs again; thus two PSA declines ≥ 0.048 ng/ml per month after nadir could be the prognostic pattern. This This finding has not been described in previous research on how different forms of PSA kinetics are associated with prognosis [5][6][7][8][9][10]. The most representative PSA prognostic patterns are pretreatment PSA, nadir, time to nadir or doubling time.…”

Section: Discussioncontrasting

confidence: 54%

“…PSA has been used in therapeutic decision making by stratifying the risk of development to CRPC [4]. Characteristics of PSA variation are summarized as patterns such as pretreatment PSA level, nadir, time to nadir, and doubling time; these patterns have clinical significances as prognostic factors to predict CRPC [5][6][7][8][9][10]. However, the accuracy of these patterns as predictors is still unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Discovery of Prostate Specific Antigen Pattern to Predict Castration Resistant Prostate Cancer of Androgen Deprivation Therapy

Kim

Park

Lee

et al. 2015

Proceedings of the ACM Ninth International Workshop on Data and Text Mining in Biomedical Informatics

Self Cite

View full text Add to dashboard Cite

Background: Prostate specific antigen (PSA) is an important biomarker to monitor the response to the treatment, but has not been fully utilized as a whole sequence. We used a longitudinal biomarker PSA to discover a new prognostic pattern that predicts castration-resistant prostate cancer (CRPC) after androgen deprivation therapy. Methods: We transformed the longitudinal PSA into a discrete sequence, used frequent sequential pattern mining to find candidate patterns from the sequences, and selected the most predictive and informative pattern among the candidates. Results: Patients were less likely to be CRPC if, after PSA values reach nadir, the PSA decreases more than 0.048 ng/ml during a month, and the decrease occurs again. This pattern significantly increased the accuracy of predicting CRPC by supplementing information provided by existing PSA patterns such as pretreatment PSA. Conclusions: This result can help clinicians to stratify men by the risk of CRPC and to determine the patient that needs intensive follow-up.

show abstract

Section: Discussioncontrasting

confidence: 54%

Section: Introductionmentioning

confidence: 99%

Discovery of Prostate Specific Antigen Pattern to Predict Castration Resistant Prostate Cancer of Androgen Deprivation Therapy

Kim

Park

Lee

et al. 2015

Proceedings of the ACM Ninth International Workshop on Data and Text Mining in Biomedical Informatics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several predictors of PFS of prostate cancer patients treated with ADT; for example, advanced age and high Gleason score for localized and locally advanced prostate cancer 19 and PSA half-time and doubling time for metastatic disease, 20 were reported previously. In the present study, we showed that the pretreatment clinical characteristics included in J-CAPRA were good predictors of PFS on univariate analysis, and clinical T and M stage on multivariate analysis.…”

Section: Discussionmentioning

confidence: 67%

Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: Clinical application and validation

et al. 2012

View full text Add to dashboard Cite

Objectives The Japan Cancer of the Prostate Risk Assessment was developed as a risk stratification instrument for patients undergoing primary androgen deprivation therapy. However, there have been no studies to validate the accuracy of the Japan Cancer of the Prostate Risk Assessment in predicting clinical outcomes. We examined whether the clinical outcomes of patients treated with combined androgen blockade could be stratified using the Japan Cancer of the Prostate Risk Assessment. Methods A total of 319 patients with prostate cancer treated with luteinizing hormone‐releasing hormone agonist plus bicalutamide were included in this analysis. Progression‐free survival, cause‐specific survival and overall survival were compared among patients divided according to the prostate‐specific antigen level at diagnosis, Gleason score on biopsy specimens, tumor–nodes–metastasis classification and Japan Cancer of the Prostate Risk Assessment score. Results The median age of the patients was 75 years, and the median prostate‐specific antigen at diagnosis was 25.4 ng/mL. A total of 102 patients (32.0%) had lymph node and/or distant metastases. On univariate analysis, the factors adopted in the Japan Cancer of the Prostate Risk Assessment points were significant predictors of progression‐free survival. On multivariate analysis, clinical T stage and M stage were significant predictors of progression‐free survival. The probabilities of progression‐free survival and cause‐specific survival were significantly different among the groups categorized according to the Japan Cancer of the Prostate Risk Assessment risk strata. The probability of overall survival in the low‐risk group was higher than in the other groups. Conclusions The progression‐free survival, cause‐specific survival and overall survival of prostate cancer patients treated by combined androgen blockade with bicalutamide were stratified by the Japan Cancer of the Prostate Risk Assessment. The Japan Cancer of the Prostate Risk Assessment score is clinically useful as a predictor of the prognosis of prostate cancer treated with combined androgen blockade.

show abstract

“…The cohort, however, included patients with either locally advanced non-metastatic disease or metastatic disease. Park et al 17 reported that a higher PSA nadir level correlated with shorter CSS. Similar to the previous study, 16 patients with lymph node metastasis were also included.…”

Section: Discussionmentioning

confidence: 99%

Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy

Wong

et al. 2015

Hong Kong Med J

View full text Add to dashboard Cite

Objective:To investigate the impact of skeletalrelated events on survival in patients with metastatic prostate cancer prescribed long-term androgen deprivation therapy.Methods: This historical cohort study was conducted in two hospitals in Hong Kong. Patients who were diagnosed with metastatic prostate cancer and prescribed androgen deprivation therapy between January 2006 and December 2011 were included. Details of skeletal-related events and mortality were examined. Results:The median follow-up was 28 (range, 1-97) months. Of 119 patients, 52 (43.7%) developed skeletal-related events throughout the study, and the majority received bone irradiation for pain control. The median actuarial overall survival and cancer-specific survival for patients with skeletalrelated events were significantly shorter than those without skeletal-related events (23 vs 48 months, P=0.003 and 26 vs 97 months, P<0.001, respectively). Multivariate analysis revealed that the adjusted hazard ratio of presence of skeletal-related events on overall and cancer-specific survival was 2.73 (95% confidence interval, 1.46-5.10; P=0.002) and 3.92 (95% confidence interval, 1.87-8.23; P<0.001), respectively. A prostate-specific antigen nadir of >4 ng/mL was an independent poor prognostic factor for overall and cancer-specific survival after development of skeletal-related events (hazard ratio=10.42; 95% confidence interval, 2.10-51.66 and Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy IntroductionProstate cancer is the most common cancer diagnosed in men in developed countries. In the United States, there were 240 890 estimated new cases in 2011, accounting for 29% of all new cancers in men and over 33 000 deaths. 1 According to the Hong Kong Cancer Registry in 2012, prostate cancer was the third most common cancer in men. 2 New knowledge added by this study • Skeletal-related events (SREs) in patients with metastatic prostate cancer significantly worsen their prognosis.• The prevalence of SREs in patients with metastatic prostate cancer is high. Implications for clinical practice or policy • Medications such as bisphosphonate therapy and receptor activator for nuclear factor κB ligand inhibitor should be considered to prevent SREs in patients with metastatic prostate cancer.Hong Kong Med J 2016;22:106-15

show abstract

Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer

Cited by 38 publications

References 20 publications

Discovery of Prostate Specific Antigen Pattern to Predict Castration Resistant Prostate Cancer of Androgen Deprivation Therapy

Discovery of Prostate Specific Antigen Pattern to Predict Castration Resistant Prostate Cancer of Androgen Deprivation Therapy

Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: Clinical application and validation

Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy

Contact Info

Product

Resources

About